Our Mission

Wilson Wolf’s mission is to create hope for cancer patients, one device at a time.

We accomplish that with our G-Rex cell and gene therapy drug product manufacturing platform.

Throughout the world on a daily basis, G-Rex is cost effectively making life-saving drug products for people in dire need.

Our Daily Ritual

Every day we strive to advance the field of  cell and gene therapy by expanding our knowledge and adapting our G-Rex platform to ensure that the CGT field is always equipped with the most economical and scalable drug product manufacturing capacity.

Our History

Wilson Wolf was established in 1998 to pioneer the development of innovative mammalian cell culture devices.

We have created cell culture devices for a wide variety of applications including monoclonal antibody production, living skin, corneal storage, porcine heart valve testing, islet transplants for type 1 diabetes, and cell and gene therapy.

“The Cell Processing Lab has shown that the culture of Tumor Infiltrating Lymphocytes (TIL), Natural Killer (NK) cells and LCL cells when using the G-Rex® flasks are superior to growth bags. G-Rex® flasks allow for cell growth at higher densities and therefore less media, growth factors, cytokine and serum additives are required...”

 

- Clinical Center, National Institutes of Health

Wilson Wolf believes in the power of uniting stakeholders for the greater good.

In January 2020, we created ScaleReady to provide the cell and gene therapy field with the foundation for a highly practical and cost effective way to make cell and gene therapy drug products.

ScaleReady created a G-Rex centric CGT manufacturing platform with the help of Wilson Wolf, Bio-Techne and Fresenius Kabi.

From R&D to commercial drug product manufacturing, ScaleReady’s G-Rex centric platform is the most cost effective, versatile, and scalable platform in the world.

Learn more at the ScaleReady Website